Showing 1 - 9 of 9 Amyotrophic Lateral Sclerosis (ALS)

Status: Enrolling

Investigator: Ericka Greene

Study Coordinator: Rachel Applegate

Phone: 713.441.9120

This study is only eligible for ALS patients who are positive for the SOD1 gene. It is a double blind, placebo controlled infusion of an antisense oligonucleotide, administered intrathecally 8 times over the course of the 28 week study. There is ... Read more >

Status: Open Not Enrolling

Investigator: Stanley Appel

Study Coordinator:

Phone:

The purpose of this protocol is to develop and maintain a clinical findings data bank including diagnostic evaluations obtained from medical records sent from prior medical evaluations, diagnostic intake evaluations and follow-up care in the Met ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Sharon Halton

Phone: 713.441.3420

The purpose of the this study to look for abnormal genes and gene expression profiles that help determine why a person develops amyotrophic lateral sclerosis (ALS) and related motor neuron diseases (MND) and why their symptoms present and progre ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Patricia Schagrin

Phone: 954.647.1625

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator:

Phone:

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen A will evaluate the safety and efficacy of a single study ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator:

Phone:

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen B will evaluate the safety and efficacy of a single study ... Read more >

Status: Enrolling

Investigator: Stanley Appel

Study Coordinator: Bing Liao

Phone: 713.363.7310

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen C will evaluate the safety and efficacy of a single study ... Read more >

Status: Open Not Enrolling

Investigator: Sheetal Shroff

Study Coordinator:

Phone:

REFINE-ALS is a prospective, observational, longitudinal, multicenter study designed to identify biomarkers to serve as quantifiable biological non-clinical measures of Edaravone effects in ALS. Epigenetic and protein biomarkers will also be inv ... Read more >

Status: Active

Investigator: Jason Thonhoff

Study Coordinator: Patricia Mendoza

Phone: 713.441.5855

This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same person whose Treg ... Read more >